Legal & General Group Plc Grows Stock Holdings in Meridian Bioscience, Inc. (NASDAQ:VIVO)

Legal & General Group Plc raised its position in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 1.9% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 108,797 shares of the company’s stock after buying an additional 1,978 shares during the quarter. Legal & General Group Plc owned about 0.25% of Meridian Bioscience worth $913,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in VIVO. Johnson Investment Counsel Inc. increased its holdings in shares of Meridian Bioscience by 6.3% during the fourth quarter. Johnson Investment Counsel Inc. now owns 21,168 shares of the company’s stock valued at $207,000 after acquiring an additional 1,251 shares in the last quarter. Stone Ridge Asset Management LLC increased its holdings in shares of Meridian Bioscience by 3.3% during the first quarter. Stone Ridge Asset Management LLC now owns 44,432 shares of the company’s stock valued at $373,000 after acquiring an additional 1,400 shares in the last quarter. Comerica Bank increased its holdings in shares of Meridian Bioscience by 4.1% during the first quarter. Comerica Bank now owns 41,378 shares of the company’s stock valued at $442,000 after acquiring an additional 1,619 shares in the last quarter. Schroder Investment Management Group increased its holdings in shares of Meridian Bioscience by 8.4% during the fourth quarter. Schroder Investment Management Group now owns 22,427 shares of the company’s stock valued at $219,000 after acquiring an additional 1,730 shares in the last quarter. Finally, Swiss National Bank increased its holdings in shares of Meridian Bioscience by 3.5% during the fourth quarter. Swiss National Bank now owns 81,800 shares of the company’s stock valued at $799,000 after acquiring an additional 2,800 shares in the last quarter. 82.77% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Meridian Bioscience from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a report on Friday, April 10th. ValuEngine downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Friday, May 1st. TheStreet upgraded shares of Meridian Bioscience from a “c” rating to a “b” rating in a report on Thursday, May 14th. William Blair upgraded shares of Meridian Bioscience from a “market perform” rating to an “outperform” rating in a report on Monday, May 11th. Finally, BidaskClub upgraded shares of Meridian Bioscience from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $8.88.

Shares of NASDAQ:VIVO opened at $23.29 on Wednesday. Meridian Bioscience, Inc. has a twelve month low of $5.51 and a twelve month high of $24.02. The company’s 50 day moving average is $16.93 and its 200 day moving average is $11.23. The company has a current ratio of 3.61, a quick ratio of 2.52 and a debt-to-equity ratio of 0.24. The company has a market cap of $932.84 million, a PE ratio of 45.67 and a beta of 0.87.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Friday, May 8th. The company reported $0.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.15. The company had revenue of $57.30 million for the quarter, compared to the consensus estimate of $57.00 million. Meridian Bioscience had a net margin of 10.47% and a return on equity of 13.59%. Equities research analysts predict that Meridian Bioscience, Inc. will post 0.74 earnings per share for the current fiscal year.

Meridian Bioscience Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Further Reading: Straddles

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.